Relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)

Clinical trials for Relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) explained in plain language.

Never miss a new study

Get alerted when new Relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) trials appear

Sign up with your email to follow new studies for Relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Engineered immune cells take on tough blood cancers in new trial

Disease control Recruiting now

This study tests a personalized cell therapy called Talikabtagene Autoleucel for people with B-cell leukemia or lymphoma that has returned or not responded to standard treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack ca…

Matched conditions: RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

Phase 2/3 • Sponsor: Health Institutes of Turkey • Aim: Disease control

Last updated Jun 27, 2026 12:01 UTC

Relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)

Get alerted when new Relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) trials appear

Engineered immune cells take on tough blood cancers in new trial